# Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck

Source: https://onco.cc/trials/nct05283226/  
OnCo record `nct05283226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by NATCO Pharma Ltd., now recruiting.

## Summary

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy is a phase 2 interventional study registered as NCT05283226 by NATCO Pharma Ltd., with 21 participants planned, started 2022-09-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: NRC-2694-A, Paclitaxel. Conditions listed: Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05283226
- Phase: 2
- Setting: A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
- Sponsor: NATCO Pharma Ltd.
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT05283226: https://clinicaltrials.gov/study/NCT05283226

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Natco Pharma](https://onco.cc/companies/natco/)

---
JSON: https://onco.cc/api/v1/entities/nct05283226.json